1. Motzer RJ. Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma. Crit Rev Oncol Hematol. 2003; 46(suppl): 33-39.
2.
2. Godley P, Kim S. Renal cell carcinoma. Curr Opin Oncol. 2002; 14: 280-285.
3.
3. Figlin R. Renal cell carcinoma: management of advanced disease. J Urol. 1999; 161: 381-387.
4.
4. Bukowski R. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 1997; 80(7): 1198-1213.
5.
5. Pantuck A, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001; 166: 1611-1623.
6.
6. Motzer R, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000; 163: 408-417.
7.
7. van Herpen CML, De Mulder PHM. Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma. Crit Rev Oncol Hematol. 2002; 41: 327-334.
8.
8. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003; 21: 3127-3132.
